The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY, rose 3% and 2.3% on Tuesday, respectively, after results from a study showed that GLP-1 drugs cut the risk of several heart conditions, kidney diseases and brain ailments. New evidence regarding the additional benefits (besides weight loss) and risks of glucagon-like peptide-1 (GLP-1) receptor agonists from a large study…